2017 AGM Question #1, page-7

ferdie , this is where they've been outed imo . Promising to have the science reviewed and if validated ,published, transdermal oxym , the most 'valuable' research was not prioritized and has apparently not been submitted after 4 long years . The concern of rejection (game over) or lack of confidence , take your pick. Terumo 'interest' appears one of comparison underscored by the paltry payment . The irony being poh never conducted a comparison test with its competitors like BASF tpgs and Terumo decided to cover all bases probably aware of tpm due to the Mylan fiasco .